Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs.

ABSTRACT: The outbreak of Coronavirus disease 2019 (COVID-19) has evolved into an emergent global pandemic. Many drugs without established efficacy are being used to treat COVID-19 patients either as an offlabel/compassionate use or as a clinical trial. Although drug repurposing is an attractive approach with reduced time and cost, there is a need to make predictions on success before the start of therapy. For the optimum use of these repurposed drugs, many factors should be considered such as drug-gene or dug-drug interactions, drug toxicity, and patient co-morbidity. There is limited data on the pharmacogenomics of these agents and this may constitute an obstacle for successful COVID-19 therapy. This article reviewed the available human genome interactions with some promising repurposed drugs for

SUBMITTER: Badary OA 

PROVIDER: S-EPMC7859465 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature